Predictive Oncology (POAI) announced additions to its leadership team and Board of Directors in support of the Company’s new digital asset treasury strategy focused on the Aethir, ATH, token. The Company announced that Shawn Matthews, CEO of DNA Holdings Venture, has joined its Board of Directors; Thomas McLaughlin, CIO of DNA Holdings Venture, has joined the leadership team as Chief Investment Officer; and biopharmaceutical veteran Sara Turken, JD, has joined as the Company’s new General Counsel.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on POAI:
- Predictive Oncology Closes $343.5M Private Placements
- Predictive Oncology Enters Securities Purchase Agreements
- Predictive Oncology Inc trading halted, news pending
- Predictive Oncology Announces $344.4M Private Placements
- Predictive Oncology prices private placements to initiate digital asset treasury